132 related articles for article (PubMed ID: 29194728)
1. CDK4 expression in chordoma: A potential therapeutic target.
Liu T; Shen JK; Choy E; Zhang Y; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2018 Jun; 36(6):1581-1589. PubMed ID: 29194728
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
4. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Zhou Y; Shen JK; Yu Z; Hornicek FJ; Kan Q; Duan Z
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1573-1582. PubMed ID: 29452249
[TBL] [Abstract][Full Text] [Related]
5. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
6. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
8. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
9. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer.
Lu J
J Hematol Oncol; 2015 Aug; 8():98. PubMed ID: 26264704
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Zhong N; Yu D; Yang M; Lu X; Zhang Q; Wei W; Jiao J; Yang X; Zhu Z; Chen S; Xiao J
J Cancer Res Clin Oncol; 2024 Feb; 150(2):95. PubMed ID: 38369555
[TBL] [Abstract][Full Text] [Related]
14. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas.
Chen Y; Li Z; Fang Q; Wang H; Li C; Gao H; Zhang Y
Int J Mol Med; 2021 Feb; 47(2):500-510. PubMed ID: 33416096
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.
Tang B; Sheng X; Kong Y; Chi Z; Si L; Cui C; Yan X; Mao L; Lian B; Li S; Wang X; Dai J; Bai X; Zhou L; Guo J
Chin Clin Oncol; 2018 Dec; 7(6):62. PubMed ID: 30180747
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
[TBL] [Abstract][Full Text] [Related]
20. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]